Cheryl R Cornwell1,2, Joy Hsu1, Lindsay K Tompkins1,3, Audrey F Pennington1, W Dana Flanders1,4, Kanta Sircar1. 1. Asthma and Community Health Branch, Division of Environmental Health Science and Practice, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA. 2. Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA. 3. Epidemic Intelligence Service, Center for Surveillance, Epidemiology and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, GA, USA. 4. Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Abstract
OBJECTIVE: This study assesses the risk of severe clinical outcomes during hospitalizations of adults with asthma and/or COPD plus COVID-19 and compares those risks with those during hospitalizations of adults with asthma and/or COPD without COVID-19. METHODS: We used data from 877 U.S. hospitals from the Premier Healthcare Database during March 2020-March 2021. Hospitalizations (n = 311,215) among patients aged ≥18 years with an ICD-10-CM diagnosis involving asthma or COPD were classified into three groups: adults with asthma (but not COPD), adults with COPD (but not asthma), and adults with both asthma and COPD. We used multivariable Poisson regression to assess associations of severe clinical outcomes [intensive care unit (ICU) admission, use of invasive mechanical ventilation (IMV), and death] and COVID-19 status. RESULTS: The percentage of hospitalizations among patients with asthma and COVID-19 resulting in ICU admission, IMV, and death were 46.9%, 14.0%, and 8.0%, respectively. These risks were higher than those among patients with asthma without COVID-19 (adjusted risk ratio [aRR], 1.17 [95% confidence interval (CI), 1.14-1.21], 1.61 [95% CI, 1.50-1.73], and 5.56 [95% CI, 4.89-6.32]), respectively. Risks of ICU admission, IMV, and death were also high among patients with COPD and COVID-19 and exceeded the corresponding risks among patients with COPD without COVID-19. CONCLUSION: Hospitalizations among patients with asthma and/or COPD with COVID-19 had a more severe clinical course than hospitalizations for asthma and/or COPD exacerbations without COVID-19. Supplemental data for this article is available online at at www.tandfonline.com/ijas .
OBJECTIVE: This study assesses the risk of severe clinical outcomes during hospitalizations of adults with asthma and/or COPD plus COVID-19 and compares those risks with those during hospitalizations of adults with asthma and/or COPD without COVID-19. METHODS: We used data from 877 U.S. hospitals from the Premier Healthcare Database during March 2020-March 2021. Hospitalizations (n = 311,215) among patients aged ≥18 years with an ICD-10-CM diagnosis involving asthma or COPD were classified into three groups: adults with asthma (but not COPD), adults with COPD (but not asthma), and adults with both asthma and COPD. We used multivariable Poisson regression to assess associations of severe clinical outcomes [intensive care unit (ICU) admission, use of invasive mechanical ventilation (IMV), and death] and COVID-19 status. RESULTS: The percentage of hospitalizations among patients with asthma and COVID-19 resulting in ICU admission, IMV, and death were 46.9%, 14.0%, and 8.0%, respectively. These risks were higher than those among patients with asthma without COVID-19 (adjusted risk ratio [aRR], 1.17 [95% confidence interval (CI), 1.14-1.21], 1.61 [95% CI, 1.50-1.73], and 5.56 [95% CI, 4.89-6.32]), respectively. Risks of ICU admission, IMV, and death were also high among patients with COPD and COVID-19 and exceeded the corresponding risks among patients with COPD without COVID-19. CONCLUSION: Hospitalizations among patients with asthma and/or COPD with COVID-19 had a more severe clinical course than hospitalizations for asthma and/or COPD exacerbations without COVID-19. Supplemental data for this article is available online at at www.tandfonline.com/ijas .
Authors: Karola S Jering; Brian L Claggett; Jonathan W Cunningham; Ning Rosenthal; Orly Vardeny; Michael F Greene; Scott D Solomon Journal: JAMA Intern Med Date: 2021-05-01 Impact factor: 21.873
Authors: Kam Sing Ho; Daniel Howell; Linda Rogers; Bharat Narasimhan; Hannah Verma; David Steiger Journal: Ann Allergy Asthma Immunol Date: 2021-02-27 Impact factor: 6.347
Authors: Felix M Reyes; Manuel Hache-Marliere; Dimitris Karamanis; Cesar G Berto; Rodolfo Estrada; Matthew Langston; George Ntaios; Perminder Gulani; Chirag D Shah; Leonidas Palaiodimos Journal: J Clin Med Date: 2021-05-13 Impact factor: 4.241
Authors: Jaber S Alqahtani; Tope Oyelade; Abdulelah M Aldhahir; Saeed M Alghamdi; Mater Almehmadi; Abdullah S Alqahtani; Shumonta Quaderi; Swapna Mandal; John R Hurst Journal: PLoS One Date: 2020-05-11 Impact factor: 3.240
Authors: Regina W Lam; Jonathan W Inselman; Molly M Jeffery; Jacob T Maddux; Matthew A Rank Journal: Ann Allergy Asthma Immunol Date: 2021-09-25 Impact factor: 6.347